Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
AbbVie Inc. stock logo
ABBV
AbbVie
$230.53
-1.0%
$212.45
$163.81
$244.81
$407.33B0.516.49 million shs650,913 shs
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
$188.90
+0.0%
$177.04
$140.68
$189.92
$454.80B0.48.90 million shs1.04 million shs
Pfizer Inc. stock logo
PFE
Pfizer
$25.98
-1.1%
$24.76
$20.92
$30.43
$147.73B0.5546.62 million shs7.88 million shs
The 10 Best AI Stocks to Own in 2025 Cover

Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
AbbVie Inc. stock logo
ABBV
AbbVie
+1.36%+0.84%+9.93%+22.38%+20.59%
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
+0.38%+1.91%+6.04%+21.07%+18.42%
Pfizer Inc. stock logo
PFE
Pfizer
-0.68%+3.18%+5.69%+2.78%-10.00%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
AbbVie Inc. stock logo
ABBV
AbbVie
$230.53
-1.0%
$212.45
$163.81
$244.81
$407.33B0.516.49 million shs650,913 shs
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
$188.90
+0.0%
$177.04
$140.68
$189.92
$454.80B0.48.90 million shs1.04 million shs
Pfizer Inc. stock logo
PFE
Pfizer
$25.98
-1.1%
$24.76
$20.92
$30.43
$147.73B0.5546.62 million shs7.88 million shs
The 10 Best AI Stocks to Own in 2025 Cover

Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
AbbVie Inc. stock logo
ABBV
AbbVie
+1.36%+0.84%+9.93%+22.38%+20.59%
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
+0.38%+1.91%+6.04%+21.07%+18.42%
Pfizer Inc. stock logo
PFE
Pfizer
-0.68%+3.18%+5.69%+2.78%-10.00%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
AbbVie Inc. stock logo
ABBV
AbbVie
2.82
Moderate Buy$229.14-1.83% Downside
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
2.68
Moderate Buy$189.880.49% Upside
Pfizer Inc. stock logo
PFE
Pfizer
2.37
Hold$28.418.15% Upside

Current Analyst Ratings Breakdown

Latest PFE, ABBV, and JNJ Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
10/7/2025
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
Citigroup
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetBuy$200.00 ➝ $213.00
10/6/2025
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
Sanford C. Bernstein
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetMarket Perform$172.00 ➝ $193.00
10/3/2025
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
UBS Group
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Set Price Target$198.00
10/3/2025
AbbVie Inc. stock logo
ABBV
AbbVie
UBS Group
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Set Price Target$251.00
10/3/2025
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
Wells Fargo & Company
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Set Price TargetEqual WeightOverweight$170.00 ➝ $212.00
10/3/2025
AbbVie Inc. stock logo
ABBV
AbbVie
Bank of America
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetNeutral$220.00 ➝ $251.00
10/3/2025
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
Wells Fargo & Company
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeEqual WeightOverweight$170.00 ➝ $212.00
10/3/2025
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
Bank of America
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetNeutral$175.00 ➝ $198.00
10/3/2025
Pfizer Inc. stock logo
PFE
Pfizer
Bank of America
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetNeutral$28.00 ➝ $30.00
10/2/2025
AbbVie Inc. stock logo
ABBV
AbbVie
HSBC
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Set Price Target$225.00
10/1/2025
Pfizer Inc. stock logo
PFE
Pfizer
UBS Group
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingNeutral$28.00
(Data available from 10/8/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
AbbVie Inc. stock logo
ABBV
AbbVie
$56.33B7.32$15.14 per share15.42$1.90 per share122.85
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
$88.82B5.12$13.18 per share14.34$29.69 per share6.36
Pfizer Inc. stock logo
PFE
Pfizer
$63.63B2.35$4.33 per share6.06$15.62 per share1.68
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
AbbVie Inc. stock logo
ABBV
AbbVie
$4.28B$2.10111.1516.701.356.45%699.66%13.64%10/31/2025 (Estimated)
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
$14.07B$9.3520.2117.072.4025.00%32.49%13.00%10/14/2025 (Estimated)
Pfizer Inc. stock logo
PFE
Pfizer
$8.03B$1.8813.978.670.8616.84%21.42%9.12%11/4/2025 (Estimated)

Latest PFE, ABBV, and JNJ Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
11/4/2025Q3 2025
Pfizer Inc. stock logo
PFE
Pfizer
$0.79N/AN/AN/A$16.94 billionN/A
10/31/2025Q3 2025
AbbVie Inc. stock logo
ABBV
AbbVie
$3.26N/AN/AN/A$15.58 billionN/A
10/14/2025Q3 2025
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
$2.78N/AN/AN/A$23.73 billionN/A
8/5/2025Q2 2025
Pfizer Inc. stock logo
PFE
Pfizer
$0.58$0.78+$0.20$0.51$13.43 billion$14.65 billion
7/31/2025Q2 2025
AbbVie Inc. stock logo
ABBV
AbbVie
$3.24$2.97-$0.27$0.52$14.93 billion$15.42 billion
7/16/2025Q2 2025
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
$2.68$2.77+$0.09$2.29$22.85 billion$23.74 billion
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
AbbVie Inc. stock logo
ABBV
AbbVie
$6.562.81%N/A312.38%53 Years
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
$5.202.75%N/A55.61%64 Years
Pfizer Inc. stock logo
PFE
Pfizer
$1.726.55%N/A91.49%16 Years

Latest PFE, ABBV, and JNJ Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
9/5/2025
AbbVie Inc. stock logo
ABBV
AbbVie
quarterly$1.643.08%10/15/202510/15/202511/14/2025
7/16/2025
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
quarterly$1.303.35%8/26/20258/26/20259/9/2025
(Data available from 1/1/2013 forward)
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
AbbVie Inc. stock logo
ABBV
AbbVie
44.14
0.74
0.61
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
0.50
1.01
0.76
Pfizer Inc. stock logo
PFE
Pfizer
0.65
1.16
0.85

Institutional Ownership

CompanyInstitutional Ownership
AbbVie Inc. stock logo
ABBV
AbbVie
70.23%
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
69.55%
Pfizer Inc. stock logo
PFE
Pfizer
68.36%

Insider Ownership

CompanyInsider Ownership
AbbVie Inc. stock logo
ABBV
AbbVie
0.08%
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
0.16%
Pfizer Inc. stock logo
PFE
Pfizer
0.06%
CompanyEmployeesShares OutstandingFree FloatOptionable
AbbVie Inc. stock logo
ABBV
AbbVie
55,0001.77 billion1.77 billionOptionable
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
138,1002.41 billion2.40 billionOptionable
Pfizer Inc. stock logo
PFE
Pfizer
81,0005.69 billion5.68 billionOptionable

Recent News About These Companies

Pfizer Inc. $PFE Shares Sold by NBT Bank N A NY
Abel Hall LLC Has $628,000 Stake in Pfizer Inc. $PFE
Brokerages Set Pfizer Inc. (NYSE:PFE) Target Price at $28.41
Life sciences sentiment rises as Pfizer deal eases tariff concerns
Down 50%, Should You Buy the Dip on Pfizer?
Down 50%, Should You Buy the Dip on Pfizer?
TrumpRx Brings Pfizer Into the Green-Is It a Buy?
Smartphone with Pfizer Logo against blue tablets and capsules Background — Stock Editorial Photography
TrumpRx Brings Pfizer Into the Green—Is It a Buy?
...

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
AbbVie stock logo

AbbVie NYSE:ABBV

$230.52 -2.31 (-0.99%)
As of 11:09 AM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers. It also provides facial injectables, plastics and regenerative medicine, body contouring, and skincare products; botox therapeutic; Vraylar for depressive disorder; Duopa and Duodopa to treat advanced Parkinson's disease; Ubrelvy for the acute treatment of migraine in adults; and Qulipta for episodic and chronic migraine. In addition, the company offers Ozurdex for eye diseases; Lumigan/Ganfort and Alphagan/Combigan for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension; Restasis to increase tear production; and other eye care products. Further, it provides Mavyret/Maviret to treat chronic hepatitis C virus genotype 1-6 infection; Creon, a pancreatic enzyme therapy; Lupron to treat advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; and Synthroid for hypothyroidism. It has collaborations with Calico Life Sciences LLC; REGENXBIO Inc.; Janssen Biotech, Inc.; and Genentech, Inc., as well as collaboration with Tentarix Biotherapeutics, LP to develop conditionally-active and multi-specific biologics for oncology and immunology. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Johnson & Johnson stock logo

Johnson & Johnson NYSE:JNJ

$188.90 +0.01 (+0.01%)
As of 11:09 AM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension. The MedTech segment includes a portfolio of products used in the interventional solutions, orthopaedics, surgery, and vision categories. The company was founded by Robert Wood Johnson I, James Wood Johnson, and Edward Mead Johnson Sr. in 1887 and is headquartered in New Brunswick, NJ.

Pfizer stock logo

Pfizer NYSE:PFE

$25.98 -0.29 (-1.10%)
As of 11:09 AM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands. It also provides medicines and vaccines in various therapeutic areas, such as biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Litfulo, Velsipity, and Cibinqo brands; amyloidosis, hemophilia, endocrine diseases, and sickle cell disease under the Vyndaqel family, Oxbryta, BeneFIX, Somavert, Ngenla, and Genotropin brands; sterile injectable and anti-infective medicines under the Sulperazon, Medrol, Zavicefta, Zithromax, and Panzyga brands; and biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Inlyta, Bosulif, Mektovi, Padcev, Adcetris, Talzenna, Tukysa, Elrexfio, Tivdak, Lorbrena, and Braftovi brands. In addition, the company involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, individual provider offices, retail pharmacies, and integrated delivery systems. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Merck KGaA; and BioNTech SE. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.